From a clinical point of view, the identification of specific TME patterns in treatment‐naïve RCC tissue that robustly predict early CRP kinetics and response would be of high relevance to stratify our patients before therapy, especially since currently available predictive tools such as PD(L)‐1 immunohistochemistry (IHC) only play a minor role in mRCC.22 Here, CRP is linked to renal cell carcinoma.